3rd ADC Payload Summit

Memo

As the ADC field becomes increasingly crowded with TOPO-1 and tubulin-based payloads, the pressure is on to identify differentiated mechanisms that can overcome resistance, improve therapeutic index, and deliver meaningful clinical advantage. Recent billion-dollar transactions, including Novartis’ acquisition of Myricx Bio and its N-myristoyltransferase inhibitor payload platform, Gilead’s $5 billion acquisition of Tubulis to strengthen next-generation ADC technologies, and Johnson and Johnson’s acquisition of Firefly Bio’s degrader antibody conjugate platform, highlight the industry’s confidence in new approaches capable of expanding the therapeutic potential of ADCs. The 3rd ADC Payload Summit is the only dedicated forum focused exclusively on payload innovation, bringing together 70+ leaders across payload chemistry, discovery biology, translational science, and R and D to tackle these challenges head-on. Through deep-dive workshops, case studies, panel discussions, and the Brand-New Curated Matchmaking Roundtables, attendees will explore novel payload classes, dual-payload strategies, resistance mechanisms, translational modelling, and emerging approaches beyond traditional cytotoxicity. Leave this meeting with the solutions to your key challenges around potency, safety, translation, and clinical success to deliver more effective therapies for patients. URLs:Tickets: https://go.evvnt.com/3758694-2?pid=5569Brochure: https://go.evvnt.com/3758694-3?pid=5569 Date and Time: On Wed, 04 Nov 2026 08:00 - Fri, 06 Nov 2026 16:15 Venue Details: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, Massachusetts, 02215, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4297.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 3099.00,Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3697.00,Academic Pricing - 2 Day Pass (Conference Only): USD 2699.00,Service Provider Pricing - 3 Day Pass (Conference + Workshop Day): USD 5297.00,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3799.00 Speakers: Andrew Phillips, Senior Director, Abbvie, Satyajit Mitra, Executive Director, Head of Oncology, Akari Therapeutics, Patrick Strout, Senior Scientist, AstraZeneca, Kashif Khan, Director, Medicinal Chemistry and Oncology, AstraZeneca, Alyson Smith, Executive Director, Biology, Callio Therapeutics, Wanping Geng, Vice President, CanWell Pharma, Kakajan Komurov, Chief Scientific and Technology Officer, Corellia AI, Paul Song, Chief Scientific Officer, Genequantum Healthcare, Prajna Behera, Senior Principal Scientist, Oncology Innovation, GlaxoSmithKline, Tara Arvedson, Chief Scientific Officer, Hexagon Bio, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Seah Lim, Chief Executive Officer, Medicovestor, Michael Weickert, Chief Executive Officer, Pacylex Pharmaceuticals, Koichi Ito, Senior Director, Biology, Prelude Therapeutics​, Krzysztof Brzózka, Chief Scientific Officer, Ryvu Therapeutics, Dori Thomas-Karyat, Chief Executive Officer, Synthis Therapeutics, Vicky Appleman, Director, Oncology Drug Discovery, Takeda